Allogene Therapeutics, Inc. — Director's Dealing 2021

Jan 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-01-14

Reporting Person: SCHMIDT ERIC THOMAS (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-14	Common Stock	S	9851	$30.6041	Disposed	1172744	Indirect
2021-01-14	Common Stock	S	5149	$31.0991	Disposed	1167595	Indirect
2021-01-15	Common Stock	S	3547	$31.6869	Disposed	1164048	Indirect
2021-01-15	Common Stock	S	11053	$32.4031	Disposed	1152995	Indirect
2021-01-15	Common Stock	S	400	$33.2850	Disposed	1152595	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	78916	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 to $33.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.17 to $33.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.